A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
FACTOR V LEIDEN (DNA)
MessageParent (primary) tube must be sent. Cannot add on this test to a previously tested sample.
Test Code
FACTV
CPT Codes
81241
Preferred Specimen
1 Lavender tube (EDTA)
Minimum Volume
1 mL
Other Acceptable Specimens
or 1 Pink tube (EDTA)
or1 Blue tube (Sodium Citrate)
or1 Blue tube (Sodium Citrate)
Instructions
Do not centrifuge; Refrigerate until testing.
Transport Temperature
Refrigerate
Specimen Stability
- 15-25°C up to 24 hours
- 2-8°C up to 15 days
- -20 to -80°C up to 3 months in freezer compatible vial
Methodology
PCR (Polymerase Chain Reaction)
Setup Schedule
M, T, W, Th, F
Report Available
Report available next day.
Reference Range
Homozygous Normal Genotype (negative)
Clinical Significance
This test aids in the evaluation of the risk for venous thrombosis. The Xpert® Factor II & Factor V Assay is a qualitative in vitro diagnostic genotyping test for the detection of Factor II and Factor V alleles from sodium citrate or EDTA anticoagulated whole blood. The test is performed on the Cepheid GeneXpert® Dx System. This test is intended to provide results for Factor II (G20210A)) and Factor V (G1691A) Leiden mutations as an aid in the diagnosis in individuals with suspected thrombophilia.
The association of Factor II and Factor V Leiden mutations with an increased risk for venous thrombosis has been well documented. The Factor II or Prothrombin mutation refers to the G to A transition at nucleotide in the untranslated region of the gene and is associated with increased plasma levels of prothrombin. Factor V Leiden (G1691A) refers to the G to A transition at nucleotide position 1691 of the Factor V gene, resulting in the substitution of the amino acid arginine by glutamine in the Factor V protein, causing resistance to cleavage by Activated Protein C (APC).
Factor II (G20210A) and Factor V Leiden (G1691A) mutations are present in 2% and 5% of the general population, respectively.
The association of Factor II and Factor V Leiden mutations with an increased risk for venous thrombosis has been well documented. The Factor II or Prothrombin mutation refers to the G to A transition at nucleotide in the untranslated region of the gene and is associated with increased plasma levels of prothrombin. Factor V Leiden (G1691A) refers to the G to A transition at nucleotide position 1691 of the Factor V gene, resulting in the substitution of the amino acid arginine by glutamine in the Factor V protein, causing resistance to cleavage by Activated Protein C (APC).
Factor II (G20210A) and Factor V Leiden (G1691A) mutations are present in 2% and 5% of the general population, respectively.
Performed By
Alverno Laboratories
Performing Laboratory
Alverno Central Lab
NMB16 (Molecular Biology, CEPHEID)
Last Updated: June 7, 2023